Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
PHASE3CompletedINTERVENTIONAL
Enrollment
363
Participants
Timeline
Start Date
December 31, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2015
Conditions
Chronic Hepatitis C Infection
Interventions
DRUG
ABT-450/r/ABT-267
Tablet; ABT-450 coformulated with ritonavir and ABT-267